Inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis are associated with adverse pregnancy outcomes. Active maternal disease during pregnancy is associated with additional negative outcomes. Anti-TNF agents are effective treatments for inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. These agents cross the placenta starting in the second trimester, with levels detected for several months after birth. This has led to safety concerns, with continued therapy during pregnancy for both the mother and the infant. This review covers retrospective and prospective data published from various cohorts of pregnant women exposed to anti-TNF agents during pregnancy. It highlights the safety of anti-TNF drugs in pregnancy, breast-feeding, and during the first year of life of the infant.

炎症性肠病、类风湿性关节炎、强直性脊柱炎、银屑病关节炎和银屑病与不良妊娠结局有关。怀孕期间活动性母体疾病与其他负面结果相关。抗 TNF 药物可有效治疗炎症性肠病、类风湿性关节炎、强直性脊柱炎、银屑病关节炎和银屑病。这些药物从妊娠中期开始穿过胎盘，在出生后几个月内检测到水平。这导致了安全问题，母亲和婴儿在怀孕期间继续接受治疗。本综述涵盖了在怀孕期间暴露于抗 TNF 药物的各种孕妇队列中发表的回顾性和前瞻性数据。它强调了抗 TNF 药物在孕期、哺乳期、